Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company with a focus on development and commercialization of innovative products for cancer care. The company develops therapies for HER2-positive breast cancer and other oncology indications, with advanced clinical trials ongoing.
Focus areas at Puma Biotechnology
The clinical trials section below shows all active and recruiting studies sponsored by Puma Biotechnology, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Puma Biotechnology is headquartered in Los Angeles, United States, founded in 2010, publicly traded under the ticker symbol PBYI. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Active Clinical Trials
Puma Biotechnology FDA-Approved Drugs (1)
Medications developed or marketed by Puma Biotechnology that have received U.S. Food and Drug Administration approval. Drug data is sourced from the openFDA database and includes brand names, generic names, approval dates, and matched rare disease indications. Where a drug treats a condition covered by Trial Friend, the disease name links directly to that disease page.
| Drug Name | Brand Name | Rare Diseases | Approval Date |
|---|---|---|---|
| NERATINIB | Nerlynx oral | Jul 17, 2017 |
Frequently Asked Questions About Puma Biotechnology
Common questions about Puma Biotechnology's rare disease programs, clinical trials, and treatments.